Lazertinib 240 mg/160 mg + Gefitinib 250 mg + Lazertinib-matching placebo 240 mg/160 mg + Gefitinib-matching placebo 250 mg
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Feb 13, 2020 → Jun 1, 2026
NCT ID
NCT04248829About Lazertinib 240 mg/160 mg + Gefitinib 250 mg + Lazertinib-matching placebo 240 mg/160 mg + Gefitinib-matching placebo 250 mg
Lazertinib 240 mg/160 mg + Gefitinib 250 mg + Lazertinib-matching placebo 240 mg/160 mg + Gefitinib-matching placebo 250 mg is a phase 3 stage product being developed by Yuhan for Non-Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04248829. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04248829 | Phase 3 | Active |
Competing Products
20 competing products in Non-Small Cell Lung Cancer